Phase 2 N=71 Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction
Heart Failure
Primary: Change in Left Ventricular End Systolic Volume (ml) — -4.4; -1.2; -3.8 mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=6,105 A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
Chronic Heart Failure With Reduced Ejection Fraction
Primary: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-Years…
Phase 2 N=56 Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)
Anemia
Primary: Change in Left Ventricular End-diastolic Volume — -6; -4 mL
Phase 3 N=5,050 A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
Heart Failure · Chronic Heart Failure With Reduced Ejection Fraction
Primary: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization — 33.6; 37.8 Parts w/ event per 100 part-yrs at risk…
Phase 3 N=3,730 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
Heart Failure
Primary: Time to the First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF) — 21.00; 15.77 Patients with events/ 100 pt-yrs…
Phase 3 N=312 This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
Heart Failure
Primary: Change From Baseline to Week 12 in Exercise Capacity as Measured by the 6-Minutes-Walking-Test (6MWT) Distance — 18.0; 13.5 Meter (m) — p=0.4236
Phase 4 N=90 Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
Heart Failure, Diastolic
Primary: Percent Change in Serum Creatinine at 72 Hours. — 4; 11; 5; 20 percent change in serum creatinine
N/A N=602 Heart Failure Optimization Study
Sudden Cardiac Death · Sudden Cardiac Arrest · Heart Failure
Primary: Percentage of Patients With LVEF Recovery at Day 90 and 180 — 222; 0; 0; 0 Participants
Phase 2 N=35 Heart Failure Polypill at a Safety Net Hospital
Heart Failure With Reduced Ejection Fraction · HIV Infections
Primary: Measured Adherence to GDMT by Pill Count — 74.6; 83.3 adherence ratio expressed in %
Phase 3 N=313 DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction
Heart Failure With Reduced Ejection Fraction (HFrEF)
Primary: Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and…
Phase 4 N=55 Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF
Heart Failure, Diastolic · Diastolic Heart Failure · Hypertension
Primary: Coronary Flow Reserve — 2.64; 2.65; 2.06 ratio
Phase 3 N=8,232 Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction
Heart Failure
Primary: Time to Cardiovascular Death or First Heart Failure Event — 39.1; 37.0 percentage of participants — p=0.0252
N/A N=349 Impact of Heart Failure Center Program on Cardiac Outcomes in Patients With Heart Failure
Death · Congestive Heart Failure
Primary: All-cause Death, Heart Failure-related Re-hospitalizations, and a Composite Outcome of Both Death and Heart Failure-related Re-hospitalizations — 36; 15; 41; 18…
Phase 2 N=26 Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction
Heart Failure
Primary: Change in Pulmonary Capillary Wedge Pressure During Exercise — -1; -4 millimeters of mercury — p=0.002
N/A N=335 Heart Failure Study: The Atlanta Cardiomyopathy Consortium
Heart Failure
Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants
Phase 3 N=6,263 Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
Heart Failure With Preserved Ejection Fraction
Primary: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure. — 512; 610 Participants — p=0.0008
Phase 4 N=37 Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Primary: Change in Plasma N-terminal Proatrial Natriuretic Peptide (NT proANP) — 47.4; 46.4 pg/mL
Phase 3 N=6,016 Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%
Heart Failure
Primary: Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events — 1083; 1283 events — p=0.0072
Phase 3 N=2,572 A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
Heart Failure With Preserved Ejection Fraction
Primary: Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12 — 0.8218; 0.9828 Ratio — p=<0.0001
Phase 2 N=28 Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction
Heart Disease · Heart Failure With Preserved Ejection Fraction · Exercise Intolerance
Primary: Exercise Pulmonary Capillary Wedge Pressure (PCWP) — 19.0; 28.0 mm Hg — p=0.0003
N/A N=103 Heart Failure Optimization at Home to Improve Outcomes (Hozho): A Pragmatic Clinical Trial in Navajo Nation
Heart Failure
Primary: Percentage That Had Increase in Classes of Guideline Directed Medical Therapy — 66.2; 13.1 percentage of patients
Phase 3 N=121 Heart Rate Reduction in Heart Failure
Heart Failure
Primary: Exercise Tolerance Assessed by 6 Minute Walking Test — 474.8; 435.7; 453.1 meters
Phase 3 N=4,822 Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Primary: Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations. — 894; 1009; 690; 797 Events — p=0.0587
Phase 4 N=324 Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
Chronic Heart Failure With Preserved Systolic Function
Primary: Effect of Dapagliflozin, as Compared With Placebo, on Heart Failure Related Health Status Using the Kansas City Cardiomyopathy Questionnaire Clinical Summary Summary…
N/A N=19 High Intensity Interval Exercise in Diastolic Heart Failure
Diastolic Heart Failure
Primary: Left Ventricular Diastolic Dysfunction — 2.1; 2; 1.3; 2.2 DD grade
Phase 3 N=52 Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH
Heart Failure, Diastolic · Pulmonary Hypertension
Primary: Mean Pulmonary Artery Pressure Measured by Right Heart Catheterization — -2.4; -4.7 mmHG
N/A N=306 Electronic Health Record-leveraged, Patient-centered, Intensification of Chronic Care for HF
Patient Engagement · Medication Optimization · Heart Failure With Reduced Ejection Fraction
Primary: Percent of Participants Who Experienced an Initiation or Intensification of Their Guideline-Directed Medical Therapy (GDMT) — 29.7; 49.0 percentage of participants
N/A N=10 The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Primary: Change in Exercise Capacity at 6 Weeks — 659.9; 300.5 seconds — p=0.47
N/A N=14 REmodeling the Left Ventricle With Atrial Modulated Pacing
Heart Failure
Primary: Number of Participants Who Remained on Study — 9; 4 participants
Phase 2 N=456 Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
Heart Failure
Primary: Change From Baseline in Log-Transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) to Week 12 — -0.28; -0.265; -0.32; -0.353 log-transformed picograms per…